SB202190 (FHPI)

Name: SB202190 (FHPI)
Brand: Selleck Chemicals
SKU: S1077
Rating: 5 (120 reviews)

For research use only.

Catalog No.S1077

120 publications

CAS No. 152121-30-7

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis.

Selleck's SB202190 (FHPI) has been cited by 120 publications

Immunity, 2021, S1074-7613(21)00210-7

PubMed: 34115964 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):798-815

PubMed: 31031016 ( click the link to review the publication )

Cancer Discov, 2018, 8(1):74-93

PubMed: 28923912 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(6):577-582

PubMed: 28459450 ( click the link to review the publication )

Nat Biotechnol, 2016, 34(11):1161-1167

PubMed: 27723727 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(7):428-36

PubMed: 23685672 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):316

PubMed: 33767160 ( click the link to review the publication )

Mol Oncol, 2021, 10.1002/1878-0261.13046

PubMed: 34165921 ( click the link to review the publication )

Carcinogenesis, 2021, bgab002

PubMed: 33417668 ( click the link to review the publication )

Neoplasia, 2021, 23(1):129-139

PubMed: 33316537 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(14)7420

PubMed: 34299039 ( click the link to review the publication )

Front Oncol, 2021, 11:657210

PubMed: 34026633 ( click the link to review the publication )

J Nutr Biochem, 2021, S0955-2863(21)00262-X

PubMed: 34407450 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(9)4463

PubMed: 33923316 ( click the link to review the publication )

Biosci Rep, 2021, 41(3)BSR20192668

PubMed: 33616153 ( click the link to review the publication )

J Mol Med (Berl), 2021, 10.1007/s00109-021-02047-5

PubMed: 33611659 ( click the link to review the publication )

Integr Biol (Camb), 2021, 13(6):139-152

PubMed: 33989405 ( click the link to review the publication )

Oncotarget, 2021, 12(9):878-890

PubMed: 33953842 ( click the link to review the publication )

Redox Biol, 2020, 28:101445

PubMed: 32037305 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):771

PubMed: 32943609 ( click the link to review the publication )

Cells, 2020, 13;9(5) pii: E1209

PubMed: 32414111 ( click the link to review the publication )

Cells, 2020, 28;9(4) pii: E822

PubMed: 32231153 ( click the link to review the publication )

J Neuroinflammation, 2020, 17(1):364

PubMed: 33261639 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )
Oxid Med Cell Longev, 2020, 2020:6584059

PubMed: 33274004 ( click the link to review the publication )

Cell Discov, 2020, 6:35

PubMed: 32550000 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(5):3203-3216

PubMed: 32053272 ( click the link to review the publication )

Eur J Immunol, 2020, 10.1002/eji.201948363

PubMed: 32022930 ( click the link to review the publication )

Sci Rep, 2020,

PubMed: 32884042 ( click the link to review the publication )

Front Pharmacol, 2020, 11:758

PubMed: 32523533 ( click the link to review the publication )

Chem Biol Interact, 2020, 317:108944

PubMed: 31935364 ( click the link to review the publication )

Int J Environ Health Res, 2020, 10.1080/09603123.2020.1739236

PubMed: 32191530 ( click the link to review the publication )

Ann Surg Oncol, 2020, 10.1245/s10434-020-08790-2

PubMed: 32632882 ( click the link to review the publication )

J Thorac Dis, 2020, 12(7):3764-3773

PubMed: 32802455 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31753849 ( click the link to review the publication )

J Dev Biol, 2020, 8(3):E12

PubMed: 32660129 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0963-y

PubMed: 32606358 ( click the link to review the publication )

Cell Prolif, 2020, e12869

PubMed: 32597573 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, 10(4):779-796

PubMed: 32561494 ( click the link to review the publication )

Mol Cell, 2019, 76(6):965-980

PubMed: 31588023 ( click the link to review the publication )

Theranostics, 2019, 9(13):3879-3902

PubMed: 31281520 ( click the link to review the publication )

Theranostics, 2019, 9(17):5065-5084

PubMed: 31410202 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):718

PubMed: 31558705 ( click the link to review the publication )

Cells, 2019, 8(7)

PubMed: 31248002 ( click the link to review the publication )

Cells, 2019, 8(9)

PubMed: 31461951 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.29305

PubMed: 31612516 ( click the link to review the publication )
Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(4)

PubMed: 30781441 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31117181 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):19409

PubMed: 31857650 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 370(2):219-230

PubMed: 31189728 ( click the link to review the publication )

Life Sci, 2019, 231:116550

PubMed: 31185235 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 116:105610

PubMed: 31518663 ( click the link to review the publication )

Mol Immunol, 2019, 111:162-171

PubMed: 31063937 ( click the link to review the publication )

J Biol Eng, 2019, 13:82

PubMed: 31709009 ( click the link to review the publication )

J Biol Eng, 2019, 13:36

PubMed: 31061676 ( click the link to review the publication )

Microb Pathog, 2019, 130:204-212

PubMed: 30885749 ( click the link to review the publication )

J Physiol Biochem, 2019, 75(4):475-487

PubMed: 31399951 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Sci Signal, 2018,

PubMed: 29511118 ( click the link to review the publication )

EBioMedicine, 2018, 36:497-507

PubMed: 30190207 ( click the link to review the publication )

Front Immunol, 2018, 9:1051

PubMed: 29896191 ( click the link to review the publication )

J Virol, 2018, 92(4)e01463-17

PubMed: 29167338 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):271-283

PubMed: 29090321 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5074

PubMed: 29568077 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:9793845

PubMed: 30693038 ( click the link to review the publication )

Am J Transl Res, 2018, 10(8):2555-2566

PubMed: 30210692 ( click the link to review the publication )
Infect Immun, 2018, 22;86(9):e00233-18

PubMed: 29986890 ( click the link to review the publication )

Eur J Pharmacol, 2018, 838:129-137

PubMed: 30196111 ( click the link to review the publication )

Toxicon, 2018, 155:1-8

PubMed: 30290166 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2018, 5(3):333-352

PubMed: 29552622 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):38-45

PubMed: 27820799 ( click the link to review the publication )

Biomaterials, 2017, 128:44-55

PubMed: 28288348 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

Free Radic Biol Med, 2017, 104:280-297

PubMed: 28131902 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)E2114

PubMed: 28991210 ( click the link to review the publication )

Sci Rep, 2017, 7:43242

PubMed: 28266583 ( click the link to review the publication )

Sci Rep, 2017, 7(1):7442

PubMed: 28785085 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 323:44-52

PubMed: 28341536 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 5(2):113-130

PubMed: 29693040 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 4(1):165-182

PubMed: 29204504 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )

J Dent Res, 2016, 95(7):769-75

PubMed: 26961489 ( click the link to review the publication )

Int J Mol Sci, 2016,

PubMed: 27782092 ( click the link to review the publication )

Sci Rep, 2016, 6:30904

PubMed: 27485764 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2016, 303:79-89

PubMed: 27174766 ( click the link to review the publication )

J Cancer, 2016, 7(8):900-9

PubMed: 27313779 ( click the link to review the publication )

J Diabetes Res, 2016, 2016:9073037

PubMed: 27635403 ( click the link to review the publication )
Oncol Rep, 2016, 35(5):3009-17

PubMed: 26986870 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Neurochem Res, 2016, 41(8):1969-81

PubMed: 27068033 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1430-8

PubMed: 27278862 ( click the link to review the publication )

Oncotarget, 2016, 7(25):37407-37419

PubMed: 27270648 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10269-78

PubMed: 26831669 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(12):1578-90

PubMed: 26376801 ( click the link to review the publication )

Inflamm Bowel Dis, 2015, 21(3):496-506

PubMed: 25647156 ( click the link to review the publication )

Cell Transplant, 2015, 24(3):573-88

PubMed: 25654487 ( click the link to review the publication )

Nat Commun, 2014, 5:3479

PubMed: 24632940 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

BMC Cancer, 2014, 14:325

PubMed: ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )

Int Immunopharmacol, 2014, 24(1): 50-58

PubMed: 25479727 ( click the link to review the publication )

J Cell Biochem, 2014, 115(5):874-88

PubMed: 24375433 ( click the link to review the publication )

Cell Transplant, 2014, 23(4-5):641-56

PubMed: 24816456 ( click the link to review the publication )

Mol Biosyst, 2014, 10(3):605-12

PubMed: 24413303 ( click the link to review the publication )

Mol Cell Biochem, 2014, 397(1-2):131-8

PubMed: 25138701 ( click the link to review the publication )

Anticancer Agents Med Chem, 2014, 14(8):1154-60

PubMed: 24934165 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description

Targets

Ferroptosis ^[11] ()	p38α ^[1] (Cell-free assay)	p38β ^[1] (Cell-free assay)
	50 nM	100 nM

In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. ^[2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. ^[3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). ^[4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. ^[6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. ^[7]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT-116	NGr6U4dHfW6ldHnvckBCe3OjeR?=	MWWyOUDPxE1?	M4C3UVMxKG2rbh?=	M4ftfGROW00EoB?=	Mk\NZZR1\W63YYTld{B1cGVibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:wIH;mJIhDTC1{IHnuJJJme3CxboPpeoUhfG9iRFG=	MmTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MkOyOVEoRjJ4MkKzNlUyRC:jPh?=
MDA-MB-231	MorBSpVv[3Srb36gRZN{[Xl?	M3vpXlIh\|ryP	NVe5OpBrOjRiaB?=		NUXFPJJxdGW\|c3Xu[ZMhS0OOMjDpcoR2[3Srb36gZpkhXE6IzsG=	NHX4Rok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGwNFg1QCd-Mk[xNFA5PDh:L3G+
rBMSCs	NInlcIpHfW6ldHnvckBCe3OjeR?=	NVvPPXlCOTBizszN	NH7RT4czNjViaB?=		NH21c5Nl\XC{ZYPz[ZMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDFVmsh[W6mIICzPC=>	Mm[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUOyOlYoRjJ4MEWzNlY3RC:jPh?=
MG63	M{e0dGZ2dmO2aX;uJGF{e2G7	MmDSNVAwOjBxM{Cg{txO	MlmxNlQhcA>?		MYXzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgcIV3\Wxib3[gdIhwe3Cqb4L5cIF1\WRicEO4JIlv\HWlZXSgZpkhS2SFbEKgbY4h[SClb37j[Y51emG2aX;uJE1l\XCnbnTlcpQhdWGwbnXy	NF7pW489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm5PFMyOid-MkW5PVg{OTJ:L3G+
MG63	MmnpRZBweHSxc3nzJGF{e2G7	NEHlWmwyOC9{MD:zNEDPxE1?	M4XsSlI1KGh?		M4\5XpNq\26rZnnjZY51dHliZHXjdoVie2WmIITo[UBieG:ydH;zbZMhemG2ZTDv[kBOTzZ\|IHnu[JVk\WRiYomgR4REdDJ?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl7OEOxNkc,OjV7OUizNVI9N2F-
HTSMCs	MUnGeY5kfGmxbjDBd5NigQ>?	M2nPVVAvOS9zL{GwJO69VQ>?	MUSxJIg>		NW\3eXp3cW6qaXLpeIVlKEORUl2tNk1qdmS3Y3XkJGhQNTFicILveIVqdiCuZY\lcJMh[W6mIH3SUmEh\XiycnXzd4lwdg>?	MkfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MkG0OlQoRjJ3OUKxOFY1RC:jPh?=
MIA PaCa-2	NV3hcGh2TnWwY4Tpc44hSXO\|YYm=	NWfFU5NwOjEEoN88US=>	NET6dIgzPCCq		NWrlbpN5emWmdXPl[EBt[WO2YYTlJIFk[3WvdXzheIlwdiCrbjDjc41jcW6jdHnvckB4cXSqIHLveIghOi2GRzDhcoQhTC2jbHzvd4XDqA>?	NIDGVm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4PFQ5QSd-MkW4PFg1QDl:L3G+
MIA PaCa-2	NIjI[Y9HfW6ldHnvckBCe3OjeR?=	M4DOSlIxyqEQvF2=	MUeyOEBp		M{XB[JJme3WudIOgbY4h[SCvb3Tld5QhcW6qaXLpeIlwdiCxZjDITWYuOc7zIIDyc5RmcW5iYXPjeY12dGG2aX;u	NUfmT3Q1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
BxPC-3	M4HNemZ2dmO2aX;uJGF{e2G7	MWGyNOKh\|ryP	MnfqNlQhcA>?		MmTCdoV{fWy2czDpckBiKG2xZHXzeEBqdmirYnn0bY9vKG:oIFjJSk0y\|rFicILveIVqdiCjY3P1cZVt[XSrb36=	NVjXWWtxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
AsPC-1	MnW4SpVv[3Srb36gRZN{[Xl?	MnThNlDDqM7:TR?=	M17KbFI1KGh?		Mm\xdoV{fWy2czDpckBiKG2xZHXzeEBqdmirYnn0bY9vKG:oIFjJSk0y\|rFicILveIVqdiCjY3P1cZVt[XSrb36=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6OES4PUc,OjV6OEi0PFk9N2F-
MIA PaCa-2	NU\HNHdOTnWwY4Tpc44hSXO\|YYm=	MXSyNOKh\|ryP	NI\vTGczPCCq		NWjZU2tr\W6qYX7j[ZMh[2ynYY\h[4Uhd2ZiUFHSVEB4cGWwIHPvcYJqdmWmIIfpeIgh\2y3Y3;z[UBidmGub3fz	MmC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEi0PFkoRjJ3OEi4OFg6RC:jPh?=
MIA PaCa-2	NHvIXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILGc40zOMLizszN	NEHP[ZUzKGh?		MVLz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U>	M33wc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEi4OFg6Lz5{NUi4PFQ5QTxxYU6=
BxPC-3	NHXD[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDqNlDDqM7:TR?=	Mkj4NkBp		NHToSWV{\W6\|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V?	MoXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEi0PFkoRjJ3OEi4OFg6RC:jPh?=
AsPC-1	M4rROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XBSFIxyqEQvF2=	MWWyJIg>		M2XUdZNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	NGr6e2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4PFQ5QSd-MkW4PFg1QDl:L3G+
HEY	MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnwUm9MOjEEoN88US=>	NEX2Z24zKGh?		MlPBd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6OES4PUc,OjV6OEi0PFk9N2F-
OVCAR-3	NGPFboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHBOohjOjEEoN88US=>	NWnDe5pEOiCq		MVvz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U>	M{\sV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEi4OFg6Lz5{NUi4PFQ5QTxxYU6=
SK-OV-3	NVHy[IpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV:yNOKh\|ryP	NWftbnhCOiCq		NHrHcpV{\W6\|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6OES4PUc,OjV6OEi0PFk9N2F-
MH7A	NXviWoduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVLOZlV6OjRiaB?=		NV76XopSemWrbn\vdoNmeyC2aHWgbY5pcWKrdH;yfUBm\m[nY4TzJI9nKFiDTh?=	M1LwdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OE[yPVY3Lz5{NUi2Nlk3PjxxYU6=
MH7A	M4Hvb2Fxd3C2b4Ppd{BCe3OjeR?=	M4nabFI2KM7:TR?=	NUnuVW53OjRiaB?=		NWnid2tOemW4ZYLz[ZMh[2WubDDjfYNt\SCjcoLld5QhcW6mdXPl[EBjgSC[QV6gZY5lKGOjdYPl[EBieG:ydH;zbZMhd2ZiY3XscJMhfmmjIHHjeIl3[XSrb36gc4YhUk6N	MnuxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6NkK5OlYoRjJ3OE[yPVY3RC:jPh?=
SCC25	NIjXN2xHfW6ldHnvckBCe3OjeR?=	NHvWZ3IzOCEQvF2=	M1X4O\|I1KGh?		Mor4bY5kemWjc3XzJIF2fG:yaHHnfUBt\X[nbB?=	M2HvcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAxLz5{NUizOFQxODxxYU6=
HaCaT	M1XFbmZ2dmO2aX;uJGF{e2G7	M4PqUlUhyrWP	NVzZOFl2OjRiaB?=		MojobY5pcWKrdIOgTWZPNc7\|LXnu[JVk\WRiQ1PMNlIheHKxZIXjeIlwdiCuZY\lcJM>	NVvJPW9GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q{PTNpPkK1PFM1OzV\|PD;hQi=>
HaCaT	NUXyV\|g6TnWwY4Tpc44hSXO\|YYm=	NFK1N5I2KML3TR?=	MmrjNlQhcA>?		NGTYPFFqdmirYnn0d{BKTk5vzsGtbY5lfWOnZDDDR2wzOiCycn;keYN1cW:wIHzleoVtew>?	NUHZToh3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q{PTNpPkK1PFM1OzV\|PD;hQi=>
HPAEpiCs	MYTGeY5kfGmxbjDBd5NigQ>?	M{exVlEwOy9zMDFOwG0>	M{G2UVEhcA>?		MVHy[YR2[2W\|IGOxVE1qdmS3Y3XkJGlESU1vMTDwdo91\WmwIHHu[EBuWk6DIHX4dJJme3Orb36gZY5lKHC{b33veIVzKGGldHn2bZR6	NF\6bJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUezOFkxOCd-MkW3N\|Q6ODB:L3G+
HPAEpiCs	MmjPSpVv[3Srb36gRZN{[Xl?	NI\VR3YyNzNxMUCg{txO	NWXQ[mZZOSCq		MVPpcohq[mm2czDTNXAue3SrbYXsZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:wIDFCpC=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd\|NEmwNEc,OjV5M{S5NFA9N2F-
HPAEpiCs	MoXUSpVv[3Srb36gRZN{[Xl?	NYrlfph[OS9\|L{GwJO69VQ>?	NW\uZWJGOSCq		M1zhWIlvcGmkaYTzJHMyWCC2aX3lMYRmeGWwZHXueIx6KHO2aX31cIF1\WRiYz3KeY4heGixc4Doc5J6dGG2aX;u	NUHGRYRlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3N\|Q6ODBpPkK1O\|M1QTByPD;hQi=>
K562	NFLacI5HfW6ldHnvckBCe3OjeR?=	NGC5Z2cyOMLizszN	MY[xxsBp	Ml3aSG1UVw>?	M{TkRolvcGmkaYTzJJF2cW6jY4LpcoUucW6mdXPl[EBxOzhiTVHQT{BxcG:\|cHjvdplt[XSrb36=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ6NEC0N{c,OjV4OESwOFM9N2F-
PANC-1	M3zwW2Z2dmO2aX;uJGF{e2G7	MWexNEDPxE1?	NEnHeY8yKGh?		MYXlcohidmOnczD0bIUh[XW2b4DoZYdq[yCnZn\lZ5TDqA>?	NWP1e5BsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N\|IzOjJpPkK1OlMzOjJ{PD;hQi=>
BxPC-3	NV60[2NOTnWwY4Tpc44hSXO\|YYm=	M3zEdlExKM7:TR?=	MYGxJIg>		NInQXVRmdmijbnPld{B1cGViYYX0c5Bp[WerYzDl[oZm[3UEoB?=	M4q1clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkOyNlIzLz5{NU[zNlIzOjxxYU6=
K562	NYT0[2llTnWwY4Tpc44hSXO\|YYm=	MUCwMlI2NTFizszN	NUSxeFdoOjRiaB?=		M1zwW5N2eHC{ZYPz[ZMhemW\|dnXyZZRzd2xvaX7keYNm\CCKMlHYJJBpd3OyaH;yfYxifGmxbh?=	MmnGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MUmzPVIoRjJ3NkG5N\|kzRC:jPh?=
THP-1	NWrFPHlMTnWwY4Tpc44hSXO\|YYm=	MlvoOUDDvU1?	MVOyJIg>		MUXzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNic3XjdoV1cW:wIH;mJGlNNTIQsTDpcoR2[2WmIHL5JFI4V0iFaH;sJJBtfXNiRmPMMVHDqA>?	NXTpe\|lMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVg3PjFpPkK1OVk5PjZzPD;hQi=>
WB	NInQR4ZHfW6ldHnvckBCe3OjeR?=	M4TMZlIx6oDLzszNxsA>	NWrlO\|ZyOzEkgJntbY4>		MWnk[YNz\WG\|ZYOgeIhmKEySUz2gc5IhVFSDLXnu[JVk\WRiSVytOkBidmRiVF7GMe6yyqCycn;keYN1cW:w	NFmwfVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWzNFY5Oid-MkW1N\|A3QDJ:L3G+
RAW 264.7	M2jk[2Z2dmO2aX;uJGF{e2G7	MoPxNVDDqM7:TR?=	MnvBN\|DjiImvaX6=		M3LIUYlv\HWlZYOgZ4hiemGldHXybZN1cWNidnHjeY9t[XSrb36gc4YhV0O\|wrC=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR4MUO5PUc,OjV2NkGzPVk9N2F-
RAW 264.7	MlnwSpVv[3Srb36gRZN{[Xl?	MWSxNOKh\|ryP	NGnzZ4Y{OOLCiX3pci=>		MXvheJRmdnWjdHXzJJRp\SCnZn\lZ5R{KG:oIF;QS{BwdiCxc4Tlc4Nt[XO2IILleJJi[3Srb36=	NFvSSJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS2NVM6QSd-MkW0OlE{QTl:L3G+
HaCaT	NX\pNWFRTnWwY4Tpc44hSXO\|YYm=	NEfEe2c1OMLizszN	M136SlMuOjRiaB?=	NYrBU\|lDTE2VTx?=	NUDzV5lSemWmdXPld{B1cGViYXPjeY12dGG2aX;uJI9nKFqRLUG=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR\|NUS4OUc,OjV2M{W0PFU9N2F-
H9c2	NGD2NIpHfW6ldHnvckBCe3OjeR?=	Mn7tOVDDqM7:TdMg	MWixNkBp		MXPy[YR2[2W\|IFzETEBz\WynYYPlJIFv\CCPTWCgcI9{ew>?	MkjuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NEW4NVgoRjJ3MkS1PFE5RC:jPh?=
HSCs	MnzlRZBweHSxc3nzJGF{e2G7	NGfzWoszPSEQvF2=	MmLUNlTDqGh?		MXvzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNiVFetbY5lfWOnZDDhZ5RqfmG2ZXSgTHNEeyCjcH;weI9{cXN?	MoHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NkG5OVAoRjJ2OU[xPVUxRC:jPh?=
THP-1	MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MY[3NkBp	NYnZXox4TE2VTx?=	NGDDd4hKSzVyPUSuO:69VQ>?	NEKx[I89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixOVA5Pyd-MkS4NVUxQDd:L3G+
MDDCs	M{HqW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1z5T\|czKGh?	NGfFSIFFVVOR	NH\RXW1KSzVyMj63{txO	M{jxVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG1NFg4Lz5{NEixOVA5PzxxYU6=
MDDCs	MlPxSpVv[3Srb36gRZN{[Xl?	MmfSNE0yPSEQvF2=	M2HuNVQ5KGh?	NHnxVnVFVVOR	MnTZd5VxeHKnc4Pld{BKTk5vzsGgZY5lKEmSLUGwJJBzd2S3Y4Tpc47DqA>?	NHLwU5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixOVA5Pyd-MkS4NVUxQDd:L3G+
MDDCs	NFr5U4JHfW6ldHnvckBCe3OjeR?=	MWmwMVE2KM7:TR?=	M33aNlQ5KGh?	MUDEUXNQ	MmLBbY5pcWKrdIOgUWlRNTGjLDDNTXAuOWJiYX7kJHJCVlSHUzDwdo9lfWO2aX;u	MnH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUWwPFcoRjJ2OEG1NFg4RC:jPh?=
MDDCs	M2fHbmZ2dmO2aX;uJGF{e2G7	M2jidFExKM7:TR?=	MoPFN{42KGh?	NYHMfVlRTE2VTx?=	M3W3ZYJtd2OtczDFRm9XKEeSLDDieZQhdm:2IG\TWkBIKG2nZHnheIVlKGWwdIL5JIlvfG9iaIXtZY4hVUSGQ4O=	M3jHSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG1NFg4Lz5{NEixOVA5PzxxYU6=
macrophages	MnLTSpVv[3Srb36gRZN{[Xl?	MnL4NgKBkc7:TR?=	MVm0MlXjiImq		M{TwVINwdXCuZYTlcJkhcW6qaXLpeJMhVVRvSVnJMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCQRj5OvmI>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhyOE[zN{c,OjR6MEi2N\|M9N2F-
PDL	MUTGeY5kfGmxbjDBd5NigQ>?	Moj6NlDDqM7:TdMg	NIq5cZc{OCCvaX6=	NE\PTVVFVVOR	NXn3W49Ce2mpbnnmbYNidnSueTDpcohq[mm2czD0bIUhfGWwc3ns[UBnd3KlZT3t[YRq[XSnZDDCUXAuOiCneIDy[ZN{cW:w	M1XNTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[xNFgyLz5{NEW2NVA5OTxxYU6=
AGS	MX;GeY5kfGmxbjDBd5NigQ>?	NHzJfIg2KM7:TR?=	MlKzN\|AhdWmw		MWPzeZBxemW\|c3XzxsAyNWmwZIXj[YQh[2G\|cHHz[U05KGGwZDDjZZNx[XOnLUOgZYN1cX[jdHnvci=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV2N{i3PEc,OjR3NEe4O\|g9N2F-
H520	NFfVUlZHfW6ldHnvckBCe3OjeR?=	MYmxNOKhyrWP	NGTzfWwyKGh?	NIr1OXNFVVOR	MnjU[IVkemWjc3XzJJRp\SCyZX3leJJmgGWmLXnu[JVk\WRiTWPINkBuWk6DIHHu[EBxem:2ZXnuJIxmfmWucx?=	M37zelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUOwOFc2Lz5{NEWzNFQ4PTxxYU6=
H1703	MnX0SpVv[3Srb36gRZN{[Xl?	NILNZ2syOMLiwsXN	MWKxJIg>	NFTXflNFVVOR	M1fYeoRm[3KnYYPld{B1cGVicHXt[ZRz\XinZD3pcoR2[2WmIF3TTFIhdVKQQTDhcoQheHKxdHXpckBt\X[nbIO=	NWez[FJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1N\|A1PzVpPkK0OVMxPDd3PD;hQi=>
H520	MlzFSpVv[3Srb36gRZN{[Xl?	MVOxNOKhyrWP	M3\HcFEzKGh?	M2Wyd2ROW09?	NILSWHFqdmirYnn0d{Bx\W2ndILlfIVlNWWuaXPpeIVlKE2VSEKgdJJwfGWrbjDzeIFjcWyrdIm=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV\|MES3OUc,OjR3M{C0O\|U9N2F-
H1703	NHrlPVhHfW6ldHnvckBCe3OjeR?=	MmT4NVDDqML3TR?=	MnvCNVIhcA>?	MV;EUXNQ	M4rMOYlvcGmkaYTzJJBmdWW2cnX4[YQu\WyrY3n0[YQhVVOKMjDwdo91\WmwIIP0ZYJqdGm2eR?=	NYTzVlF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1N\|A1PzVpPkK0OVMxPDd3PD;hQi=>
H520	Ml:zSpVv[3Srb36gRZN{[Xl?	NUXPdlFoOTEEoNM1US=>	NYr1TVl{PiCq	MoHXSG1UVw>?	MWTzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgcIV3\Wy\|IH;mJJVjcXG3aYTpck1kd26sdXfheIVlKE2VSEKgbY4heGWvZYTy[Zhm\C22cnXheIVlyqClZXzsJIxqdmV?	M1Xtc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUOwOFc2Lz5{NEWzNFQ4PTxxYU6=
H1703	M2TnZ2Z2dmO2aX;uJGF{e2G7	NV7mOlZQOTEEoNM1US=>	NFvMc2w3KGh?	M{HsTmROW09?	Mme1d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIxmfmWuczDv[kB2[mmzdXn0bY4u[2:waoXnZZRm\CCPU1iyJIlvKHCnbXX0doV5\WRvdILlZZRm\MLiY3XscEBtcW6n	NIn2SlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWzNFQ4PSd-MkS1N\|A1PzV:L3G+
MC3T3-E1	NYCxcIRiTnWwY4Tpc44hSXO\|YYm=	MU[wMlMwOy9\|MDFOwG0>	NGG1cnoyKGh?		MWLheJRmdnWjdHXzJHRPTi4QsT3pcoR2[2WmIF3NVE06KGW6cILld5Nqd25iaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?=	NFjuT3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWwNlY6Pid-MkS1NFI3QTZ:L3G+
MC3T3-E1	MU\GeY5kfGmxbjDBd5NigQ>?	MnrGN\|Ah\|ryP	NUTLZ5J4OSCq		MoHIZZR1\W63YYTld{BVVkZvzsGtd5RqdXWuYYTl[EBxOzhiTVHQT{BxcG:\|cHjvdplt[XSrb36=	MoHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MEK2PVYoRjJ2NUCyOlk3RC:jPh?=
HUVECs	MofISpVv[3Srb36gRZN{[Xl?	NH;mTpUyOMLiwsXN	MVixJIg>		NWDrb5NNcW6qaXLpeJMhXE6ILd8xMYlv\HWlZXSgR3hEVDFicILv[JVkfGmxbh?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR6N{m2OEc,OjR2OEe5OlQ9N2F-
AGS	M1S0TWZ2dmO2aX;uJGF{e2G7	NFTse4EyOMLiwsXN	M3fNd\|MxyqCvaX6=		NH;Neo5qdmirYnn0d{BKVC1zzsKtbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKHB\|OB?=	M4fWNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEe5OlgyLz5{NES3PVY5OTxxYU6=
MKN-45	M3\BUWZ2dmO2aX;uJGF{e2G7	NYr6SZU1OTEEoNM1US=>	NI\lVYY{OMLibXnu		M2r3OolvcGmkaYTzJGlNNTIQsj3pcoR2[2WmIHHjeIl3[XSrb36gc4YheDN6	MnLRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{m2PFEoRjJ2NEe5OlgyRC:jPh?=
AGS	NF\reWNHfW6ldHnvckBCe3OjeR?=	MXWxNOKhyrWP	Mn;DN\|DDqG2rbh?=		NWXhOXM1[XS2ZX71ZZRmeyCLTD2x{tIucW6mdXPl[EBISSClZXzsJI1q\3KjdHnvckBidmRiaX72ZZNqd25?	NGLGR449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3PVY5OSd-MkS0O\|k3QDF:L3G+
MKN-45	MVHGeY5kfGmxbjDBd5NigQ>?	M4j3R\|ExyqEEtV2=	M3L4cFMxyqCvaX6=		M4GyT4F1fGWwdXH0[ZMhUUxvMd8yMYlv\HWlZXSgS2Eh[2WubDDtbYdz[XSrb36gZY5lKGmwdnHzbY9v	NXnPeIkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O\|k3QDFpPkK0OFc6PjhzPD;hQi=>
AGS	M3XSSmZ2dmO2aX;uJGF{e2G7	Mn;UNVDDqML3TR?=	NGThelE{OMLibXnu		NIXXdpl{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDJcE0y\|rJvaX7keYNm\CCPTWCyJIFv\CCPTWC5JI1TVkFiZYjwdoV{e2mxbh?=	MnfpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{m2PFEoRjJ2NEe5OlgyRC:jPh?=
MKN-45	M1HyPGZ2dmO2aX;uJGF{e2G7	NYHKW5g6OTEEoNM1US=>	NXLoZWFiOzEEoH3pci=>		NX60U5k4e2mpbnnmbYNidnSueTDk[YNz\WG\|ZYOgTYwuOc7{LXnu[JVk\WRiTV3QNkBidmRiTV3QPUBuWk6DIHX4dJJme3Orb36=	M3u2PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEe5OlgyLz5{NES3PVY5OTxxYU6=
DCs	NXjFdoIzTnWwY4Tpc44hSXO\|YYm=	NFTBR5AzOMLizszN	NXS0VmllOcLiaB?=		NWjOPXdM\GWlcnXhd4V{KEmOLUGyJJBzd2S3Y4Tpc44>	NHiyd5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzOFY{Pid-MkS0N\|Q3OzZ:L3G+
HUVEC	NIXV[YRHfW6ldHnvckBCe3OjeR?=	M3;DblIxKM7:bdMg	NVPMUXZQPSCq	M{P3d2ROW09?	M37rdJJm\HWlZYOgZ5l1d2urbnWg[ZhxemW\|c3nvckBt\X[nbIOgbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK=	NIS4UY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG4PVA3Oid-MkSxPFkxPjJ:L3G+
A 549	MW\GeY5kfGmxbjDBd5NigQ>?	M2HWXlUxKM7:TR?=	NFHaWpAyKGh?		M4D3e4Rm[3KnYYPld{B1cGVibHX2[Ywhd2ZiSVytPOKh	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5OU[4PEc,OjRzN{m2PFg9N2F-
H520	NHvSdoFHfW6ldHnvckBCe3OjeR?=	MXW1M\|ExKM7:TR?=	M1zyfVEhcA>?	M{PiOGROW09?	Mmjk[IVkemWjc3XzJG1UUDJicILveIVqdiCjczD3[YxtKGG\|IH3SUmEhdGW4ZXzzJIlvKGenZnn0bY5q[i2neIDvd4VlKGOnbHy=	NXTCXZE3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN\|g6ODNpPkK0NVM5QTB\|PD;hQi=>
H1703	MYLGeY5kfGmxbjDBd5NigQ>?	M1TKWlUwOTBizszN	NH7UUGMyKGh?	M1fLUmROW09?	NEHjNlZl\WO{ZXHz[ZMhVVOKMjDwdo91\WmwIHHzJJdmdGxiYYOgcXJPSSCuZY\lcJMhcW5iZ3XmbZRqdmmkLXX4dI9{\WRiY3XscC=>	NV;PRmZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN\|g6ODNpPkK0NVM5QTB\|PD;hQi=>
H520	NELWS5hHfW6ldHnvckBCe3OjeR?=	NVjrcHFMOTEEoNM1US=>	MXuxNkBp	MXjEUXNQ	NXmxc45o\GWlcnXhd4V{KE2VSEKgcXJPSSCjbnSgdJJwfGWrbjDzeIFjcWyrdImgbY4h\2WoaYTpcoljNXS{ZXH0[YQhVlOFTFOgZ4VtdHN?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF\|OEmwN{c,OjRzM{i5NFM9N2F-
H1703	NFvYd4RHfW6ldHnvckBCe3OjeR?=	NILIOogyOMLiwsXN	MVSxNkBp	MorGSG1UVw>?	MlHL[IVkemWjc3XzJG1UUDJibWLORUBidmRicILveIVqdiC\|dHHibYxqfHliaX6g[4VncXSrbnniMZRz\WG2ZXSgUnNEVENiY3XscJM>	M17ubVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUO4PVA{Lz5{NEGzPFkxOzxxYU6=
MCF-7	NVHVO2pQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\NS5kyOMLizszN	M3nmWVI1yqCq		MkX5bY5pcWKrdIOgeIhmKEOUMUC4MYlv\HWlZXSgZ4VtdCCmZXH0bC=>	M{Lv[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUK4PFU{Lz5{NEGyPFg2OzxxYU6=
HPAEpiCs	NFvBZmJHfW6ldHnvckBCe3OjeR?=	Mlv4NE4yNzFxMUCg{txO	MXuxJIg>		M1;4TolvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIHPQUGEzyqCycn;0[YlvKGGwZDDtVm5CKGW6cILld5Nqd25?	M4rDd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2ME[5NVU5Lz5{NEC2PVE2QDxxYU6=
podocytes	M2XoVWZ2dmO2aX;uJGF{e2G7	M2PQ[lExyqEQvF2=	MX[xJIg>		NHPaZWdqdmirYnn0d{BVT0cQskGtbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKHB\|OF3BVGsh[W6mIFXyb\|EwOsLi	NGfGOFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECzOlIyOid-MkSwN\|YzOTJ:L3G+
MCF-7	MWTGeY5kfGmxbjDBd5NigQ>?	M2SwOVExyqEQvF2=	NWnSTJYyOSCq	M3Tq[WROW09?	MoHkdoVlfWOnczD0bIUhX0FvaX7keYNm\CCyaH;zdIhwenmuYYTl[EBxOzhiTVHQTy=>	M136fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG5NFkxLz5{NECxPVA6ODxxYU6=
MCF-7	NV7OfFZDTnWwY4Tpc44hSXO\|YYm=	MUWxNOKh\|ryP	NFXHR4EzPCCq	MYrEUXNQ	NYnNV29DcW6lcnXhd4V{KHSqZTDXRU1qdmS3Y3XkJIFxd3C2b4Ppdy=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzOUC5NEc,OjRyMUmwPVA9N2F-
HAPI	M3rv[2Z2dmO2aX;uJGF{e2G7	MonGNVAwOjBxNEFCpO69VQ>?	NE\ibJgyKGh?		MXzpcohq[mm2czDUR2RFNWmwZIXj[YQheDN6L1rOT{BOSVCNIIDoc5NxcG:{eXzheIlwdg>?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4OUGyNEc,OjN7NkmxNlA9N2F-
HAPI	MkjPSpVv[3Srb36gRZN{[Xl?	M3OzelIxyqEQvF5CpC=>	MmP6NUBp	M3\aW2ROW09?	MY\heJRmdnWjdHXzJHRETERvaX7keYNm\CCjY4TpeoF1cW:wIH;mJIlPV1NiYX7kJJBzd2S3Y4Tpc44>	M33Sd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[5NVIxLz5{M{m2PVEzODxxYU6=
HepG2	MmjqSpVv[3Srb36gRZN{[Xl?	MlrQN\|UxKG6P	M4HKSlI1KGh?		NHnROmdqdmirYnn0d{B1cGViZHXneYVtcW5vaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QE2DUFu=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl\|M{G5PEc,OjN7M{OxPVg9N2F-
AGS	NETNOFZHfW6ldHnvckBCe3OjeR?=	MXOxNOKh\|ryP	Mn;SN\|AhdWmw		M{jJNIlvcGmkaYTzJINie3Cjc3WtN{Bi[3SrdnH0bY9vKGGwZDDpcohq[mm2aX;uJI9nKEWUSx?=	MoLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NUC5PVQoRjJ\|OEWwPVk1RC:jPh?=
HepG2	MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEezVmYxNTVyIN88US=>	MojFOFghcA>?		NELR[lZqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzhyN{WwPEc,OjN6MEe1NFg9N2F-
BEL7404	NF;mSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LCflAuPTBizszN	NIjBR\|Q1QCCq		NXXuXVZmcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	M3n0[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEC3OVA5Lz5{M{iwO\|UxQDxxYU6=
HL7702	MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPSNE02OCEQvF2=	NIi3N4g1QCCq		MXrpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MlX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MEe1NFgoRjJ\|OEC3OVA5RC:jPh?=
HepG2	MnXFSpVv[3Srb36gRZN{[Xl?	M1vkdVAuPTBizszN	NH\D[YEzPCCq		NGPCNJpqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIICzPEBld3ewc4Ty[YFuKHC{b4TlbY5{KE2DUFvBVGszNCCDVF[yMEBOW0tzIHHu[EBJW1B{NzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MnPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MEe1NFgoRjJ\|OEC3OVA5RC:jPh?=
BEAS-2B	NV7hRmoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDRNVAh\|ryP	MWqzNEBucW5?		M4juPJJmfmW{c3XzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSCrbnT1Z4VlKGK7IFjDTS=>	MonDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OESwN\|QoRjJ\|N{i0NFM1RC:jPh?=
BEAS-2B	MVzDfZRwfG:6aYT5JGF{e2G7	NH[1S2EyOCEQvF2=	NFPvfoM{OCCvaX6=		NXjkZWhrcW6qaXLpeIVlKHSqZTDpcoNz\WG\|ZTDpckBNTEhiYX7kJGlNNThiZYjwdoV{e2mxbh?=	Mki2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OESwN\|QoRjJ\|N{i0NFM1RC:jPh?=
BEAS-2B	M1;SNWZ2dmO2aX;uJGF{e2G7	NFrC[IEyOCEQvF2=	MWezNEBucW5?		MU\k[YNz\WG\|ZYOgeIhmKGyndnXsd{Bw\iClYYPwZZNmNTNuIFLh[EBidmRiZnHz	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd6NECzOEc,OjN5OESwN\|Q9N2F-
H9c2	MW\GeY5kfGmxbjDBd5NigQ>?	MWqwMlAyNzBwMT:xJO69VQ>?	M{jNPVEhcA>?		NEDZdIdifHSnboXheIV{KFSQRj5OtU1qdmS3Y3XkJG1OWC17IHX4dJJme3Orb36sJI1TVkFibHX2[Yx{NCCjbnSgdJJwdW:2ZYKgZYN1cX[rdIm=	MljrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5N{SyOVIoRjJ\|N{e0NlUzRC:jPh?=
H9c2	NYL6fZpNTnWwY4Tpc44hSXO\|YYm=	MoO4NUDPxE1?	MVexJIg>		Mk\tdoVlfWOnczDUUmYu\|rFiZHny[YN1dHlic4TpcZVt[XSnZDDwN\|ghVUGSSzDwbI9{eGixconsZZRqd25?	M3X3N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{e0NlUzLz5{M{e3OFI2OjxxYU6=
U937	M4nyPWZ2dmO2aX;uJGF{e2G7	MXGxNOKh\|ryPwrC=	MXexJIg>		M2fOfYFjem:pYYTld{B1cGViY3Hm[oVqdmViZX\m[YN1KG:wIF3LVE0yKGGwZDDQVFJC[87zIH3SUmEhfHKjboPjdolxfGmxbnHsJIxmfmWucx?=	NEDleY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewO\|M5Pyd-MkO3NFc{QDd:L3G+
U937	NX3TSFdPTnWwY4Tpc44hSXO\|YYm=	M{S4fFExyqEQvF5CpC=>	M2S4OVEhcA>?		M4LFToFjem:pYYTld{Bk[W[oZXnu[U1qdmS3Y3XkJG1MWC1zIHTve44uemWpdXzheIlwdiCjbnSgVHAzSWQQsTD1dE1z\We3bHH0bY9v	M{nUe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{C3N\|g4Lz5{M{ewO\|M5PzxxYU6=
U937	NISxc3FHfW6ldHnvckBCe3OjeR?=	MXexNOKh\|ryPwrC=	MoLQNUBp		NHzGTIJ{fXCycnXzd4V{KGNvSoXuJIFv\CCFUlXCJJBpd3OyaH;yfYxifGmxbjDpckBk[W[oZXnu[U11emWjdHXkJINmdGy\|wrC=	M4HKRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{C3N\|g4Lz5{M{ewO\|M5PzxxYU6=
A549	NVTsSm1GTnWwY4Tpc44hSXO\|YYm=	MXSwMlMwOy9\|MDFOwG0>	NGnue4cyKGh?		MVLzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNiQWTQ{tNUNW2nZHnheIVlKEORWD2yJJBzd3SnaX6gZY5lKG2UTlGg[ZhxemW\|c3nvckBidmRicILvcY91\XJiYXP0bZZqfHoEoB?=	Mlr2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4OEC2O\|QoRjJ\|NkiwOlc1RC:jPh?=
A549	M36zXGZ2dmO2aX;uJGF{e2G7	M4fXNFExyqEQvF5CpC=>	NITtUFYxNTNyIH3pci=>		Ml\5bY5pcWKrdIOgRXRR\|rOVIHnu[JVk\WRicESyM5A1PCCPQWDLJIFv\CCyM{igUWFRUyCyaH;zdIhwenmuYYTpc44>	NIjXdW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[4NFY4PCd-MkO2PFA3PzR:L3G+
A549	MUPGeY5kfGmxbjDBd5NigQ>?	M4jDNFExyqEQvF5CpC=>	NH;BW48yKGh?		M3niV4lvcGmkaYTzJGFVWM7\|UzDpcoR2[2WmIF7GMe67SiCyNkWgd5VjfW6rdDDwbI9{eGixconsZZRqd25iYX7kJG5HNc78QjDwdo9ud3SncjDhZ5Rqfmm2eR?=	NV20NWhHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PFA3PzRpPkKzOlgxPjd2PD;hQi=>
A549	MYDGeY5kfGmxbjDBd5NigQ>?	M2rESVExyqEQvF5CpC=>	Mly2NUBp		MlvSdoVlfWOnczDBWHDPu1Nvc4TpcZVt[XSnZDDjVGxCOiCyaH;zdIhwenmuYYTpc47DqA>?	MlfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4OEC2O\|QoRjJ\|NkiwOlc1RC:jPh?=
A549	M3TyS2Z2dmO2aX;uJGF{e2G7	M4HCN\|ExyqEQvF5CpC=>	MoH6NUBp		M2ezepJm\HWlZYOgRXRR\|rOVLXXubIFv[2WmIHXufplu[XSrYzDhZ5Rqfmm2eTDv[kBkWEyDMtMg	NX;1N2RMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PFA3PzRpPkKzOlgxPjd2PD;hQi=>
PC12	NFzYTmZHfW6ldHnvckBCe3OjeR?=	M{T6NlExNzJyL{SwJO69VQ>?	NVm3U4lDOcLiaB?=		M{nRbolvcGmkaYTzJGpPUyCjbnSgdFM5	NYrPeHFqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PFQ{PTdpPkKzOVg1OzV5PD;hQi=>
HK-2	Mki5RZBweHSxc3nzJGF{e2G7	NISyfpUzOMLizszN	M1OzeFI1KGh?		MnznbY5pcWKrdIOgSXJMKGGwZDDwN\|hOSVCN	NX7IXZVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFMyPTFpPkKzOVQ{OTVzPD;hQi=>
H9c2	NEfk[2NHfW6ldHnvckBCe3OjeR?=	NFXVT\|AyyqEQvF2=	NH7aOosyKGh?		MmnOdoVlfWOnczDUUmYu\|rFvaX7keYNm\CCPTWCtPUBuWk6DIHzleoVteyCjbnSgdJJwdW:2ZYKgZYN1cX[rdIm=	NHS4PVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O1N\|Y6QSd-MkOzOVM3QTl:L3G+
H9c2	MVnGeY5kfGmxbjDBd5NigQ>?	NICxNmwyyqEQvF2=	NVzjXWYxOSCq		MU\y[YR2[2W\|IGTOSk3PuS2nbnjhcoNm\CCDUD2xJJBzd22xdHXyJIFkfGm4aYT5	NWWyWpJORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOVM3QTlpPkKzN\|U{Pjl7PD;hQi=>
H1650	M2XETGZ2dmO2aX;uJGF{e2G7	Ml3RNVDDqM7:TdMg	M{LVWVEhcA>?	NULIVHZlTE2VTx?=	NGDtOYxl\WO{ZXHz[ZMh[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVteyCxZjDFVmNEOSCrbjDwZYNtcXSjeHXsMYV5eG:\|ZXVCpINmdGy\|	NYXURmdDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNlg3QTZpPkKzNlI5Pjl4PD;hQi=>
H1703	M4OzTmZ2dmO2aX;uJGF{e2G7	M2myc\|ExyqEQvF5CpC=>	NFjzbVIyKGh?	MXjEUXNQ	NWCxbI5j\GWlcnXhd4V{KGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdHNib3[gSXJESzFiaX6gdIFkdGm2YYjlcE1mgHCxc3XkxsBk\Wyucx?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ{OE[5Okc,OjN{Mki2PVY9N2F-
H1650	NVLmTVc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnSRWYyOMLizszNxsA>	M1\JbFEhcA>?	NFvW[mtFVVOR	Mlj0[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>?	M{nGT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkK4Olk3Lz5{M{KyPFY6PjxxYU6=
H1703	NXnJO2ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH:4cVYyOMLizszNxsA>	NX;JWmJoOSCq	MnizSG1UVw>?	NXrpOHpQ\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?=	M4TBSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkK4Olk3Lz5{M{KyPFY6PjxxYU6=
medulloblastoma cells	MXXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				Mmn3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCvZXT1cIxw[myjc4TvcYEh[2WubIOgbIFz[m:{aX7nJIhmfGW{b4r5[492eyCydHPoNUBo\W6nIHL5JG1VXCCjc4PhfUwhTUN3MDC9JFMvODB4IN88UU4>	Mn;xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2MUe2N\|EoRjF5NEG3OlMyRC:jPh?=
neural precursor cells	NYPWT4RrSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				MknuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCwZYXyZYwheHKnY4Xyd49zKGOnbHzzJIJ6KE2WVDDhd5NigSxiRVO1NEA:KDhwME[zJO69VS5?	NIT0W2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{SxO\|Y{OSd-MUe0NVc3OzF:L3G+
RAW264.7	M1vEb2FvfGmrbn\sZY1u[XSxcomgZZN{[Xl?		MWGxNEBucW6\|		NGWxb2RCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJHJCXzJ4ND63JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgUm8heHKxZIXjeIlwdiCrbnP1ZoF1\WRiZn;yJFExKG2rboOgdJJqd3JidH:gUHBUNWOqYXzs[Y5o\SCvZXHzeZJm\CCjZoTldkAyQCCqcoOgZpkhT3KrZYPzJI1mfGixZDygTWM2OCB;IEG2JO69VS5?	NYnPRZdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4N\|E4QThpPkKyPFMyPzl6PD;hQi=>
BL21(DE3)	M1roO2Z2dmO2aX;uJIF{e2G7		MUK2NEBucW6\|		M4nObGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDIbZM3NXSjZ3fl[EBDWkR2IHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFqRFWzLUBk\WyuczD1d4lv\yCkaX;0bY56dGG2ZXSgbIl{fG:wZTDIOEBx\XC2aXTlJIF{KHO3YoP0doF1\SCjZoTldkA3OCCvaX7zJIJ6KEGucHjhV4Nz\WWwIHHzd4F6NCCLQ{WwJF0hOy52IN88UU4>	NUj3[pplRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixPVU4OjNpPkK4NVk2PzJ\|PD;hQi=>
RAW264.7	NEXRZ\|NHfW6ldHnvckBie3OjeR?=				M2[3WXBzd3SnY4Tpc44h[WejaX7zeEBD[WOrbHz1d{BidnSqcnHjbZMheHKxdHXjeIl3\SCjboTp[4VvKGGwZDDs[ZRp[WxidH;4bY4u\GmyaITo[ZJq[SC2b4jpckBkcGmvZYLpZ{Bxem:2ZXnuJI1m\GmjdHXkJIN6fG:2b4jpZ4l1gSCrbjDtc5V{\SCUQWeyOlQvPyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fS=>	MnvaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2OEW1NFQoRjF5NEi1OVA1RC:jPh?=
A673	NFX4eIVyUFSVIHHzd4F6				Ml71dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	MmXrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	NYrDN\|hveUiWUzDhd5NigQ>?				MV;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	NFH3RXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	MlzqdWhVWyCjc4PhfS=>				MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	MlXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	MVTxTHRUKGG\|c3H5				NXW3cnhYeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	NIK3PWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	MXXxTHRUKGG\|c3H5				NIiwZ4FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1zMjDj[Yxtew>?	NXTBbYFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5	M3\0XZFJXFNiYYPzZZk>				MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDMRW4uPSClZXzsdy=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	MUDxTHRUKGG\|c3H5				MkDKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	Mkj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	M2DndJFJXFNiYYPzZZk>				MlXKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIuTUKlMTDj[Yxtew>?	MmnXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	NUPn[o9YeUiWUzDhd5NigQ>?				MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	M1jFWJFJXFNiYYPzZZk>				NWqxOlRReUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl?	NVrxZlEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	MkjGdWhVWyCjc4PhfS=>				NHizdGtyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1\|NzDj[Yxtew>?	NG\BcGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	MVLxTHRUKGG\|c3H5				Mkm4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUWchPjNiKE[tWGchWiliY3XscJM>	NXTSXGNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30	NW\ydGRyeUiWUzDhd5NigQ>?				NYTkZVQxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh\|MDDj[Yxtew>?	NX7Vco9vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	M3rxWpFJXFNiYYPzZZk>				NXj3OpFbeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	M4T1ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	MVHxTHRUKGG\|c3H5				MWLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	MkWxdWhVWyCjc4PhfS=>				M4jU[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	NV7kVHVJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	MmHydWhVWyCjc4PhfS=>				MoHEdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIyPjR\|IHPlcIx{	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NXXu[YRYeUiWUzDhd5NigQ>?				M1P4dpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN?	MnvxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	NXPHUWNteUiWUzDhd5NigQ>?				NVLubG1XeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NV6yelBvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	NHHyVoFyUFSVIHHzd4F6				NH;4RVdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{	NF;FNZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	NXXzNXFYeUiWUzDhd5NigQ>?				M1;qTpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOThiY3XscJM>	NHe5UVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2; PubMed: 26844273 EBioMedicine CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition of p38 by immunoblot. pJNK1 / pJNK2 / JNK1 / JNK2 ; PubMed: 18222647 Cell Signal A549 cells were treated with DMSO control or with 10 µM of SB202190 for 0.5, 1, 2, 3, 4, or 6 hours, and pJNK and unphosphorylated JNK were detected as described.	26844273 18222647
Immunofluorescence	p-p38 / MMP9; PubMed: 24479681 Mol Cancer Immunocytochemical staining and confocal microscopy confirmed that IL-1β increased activation of p38 (red), and MMP2 and MMP9 (green) expression in MKN-45 GA cells; these effects were blocked by p38 siRNA or the p38 inhibitor SB202190.	24479681
Growth inhibition assay	Cell viability ; PubMed: 26844273 EBioMedicine Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h. Lower panel: CRC cells were treated with SB202190 at 10 μM for different times. Cell growth was measured by SRB assay (means ± s.d. in triplet, n = 3 in triplet).	26844273

In vivo

Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. ^[5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. ^[8]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase assays: The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-³³P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-³³P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research: ^[2]	- Collapse Cell lines: Jurkat, and HeLa Concentrations: Dissolved in DMSO, final concentrations ~50 μM Incubation Time: 24 hours Method: Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining. (Only for Reference)
Animal Research: ^[5]	- Collapse Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG Dosages: 12.5 μg Administration: Administered via i.d. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	66 mg/mL (199.19 mM)
	Ethanol	12 mg/mL (36.21 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%H2O For best results, use promptly after mixing.	8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download SB202190 (FHPI) SDF

Molecular Weight	331.34
Formula	C₂₀H₁₄N₃OF
CAS No.	152121-30-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1=CC(=CC=C1C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Selective p38 MAPK Inhibitor

BIRB 796 (Doramapimod) : p38α-selective, Kd=0.1 nM.
Most Potent p38 MAPK Inhibitor

Skepinone-L ^New : p38α-MAPK, IC50=5 nM.
p38 MAPK Inhibitor in Clinical Trial

VX-702 : Phase II for Rheumatoid Arthritis.
Newest p38 MAPK Inhibitor

Skepinone-L ^New : Selective p38α-MAPK inhibitor with IC50 of 5 nM.

Related p38 MAPK Products

Pexmetinib (ARRY-614) ^New

Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.
SB239063 ^New

SB239063 is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.
Ravoxertinib (GDC-0994) ^New

Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
SB203580

SB203580 (RWJ 64809, PB 203580) is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM. SB203580 induces mitophagy and autophagy.

Features:First reported p38 inhibitor.
Doramapimod (BIRB 796)

Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with K_d of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.

Features:The first p38 MAPK inhibitor to be tested in a phase III clinical trial.
Ralimetinib (LY2228820) dimesylate

Ralimetinib (LY2228820) dimesylate is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.
Losmapimod (GW856553X)

Losmapimod (GW856553X, GW856553, GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pK_i of 8.1 and 7.6 for p38α and p38β, respectively. P38 MAPKs are involved in cell differentiation, apoptosis and autophagy. Phase 3.
PH-797804

PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.
VX-702

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Features:Highly selective, orally active inhibitor of p38 MAPK.
TAK-715

TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

SB202190 (FHPI)